Dual mTORC1/C2 inhibitors: Gerosuppressors with potential anti-aging effect

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23052-23054

  Sousa Victor, Pedro ^a,b   García Prat, Laura ^b   Muñoz Cánoves, Pura ^b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Aging; Geroconversion; MTOR; Quiescence; Senescence

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; DOXORUBICIN; ETOPOSIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN P21; RAPAMYCIN; TORIN1; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MTOR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PLASMA PROTEIN; PURINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TORIN;

ADENOCARCINOMA CELL LINE; ANTIAGING ACITVITY; ARTICLE; BREAST ADENOCARCINOMA; CELL AGING; CELL CULTURE; CELL CYCLE ARREST; CELL GEROCONVERSION; CELL LINE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME INHIBITION; FIBROBLAST; HT1080 CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; SENESCENCE; SKBR3 CELL LINE; WI38T CELL LINE; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN;

AGING; ANIMALS; BLOOD PROTEINS; CELL AGING; HUMANS; INDOLES; MULTIPROTEIN COMPLEXES; PURINES; TOR SERINE-THREONINE KINASES;

EID: 84943388545     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5563     Document Type: Article

References (17)

1. Lopez-Otin, C., et al., The hallmarks of aging. Cell, 2013. 153:1194-217.
2. Madaro, L. and L. Latella, Forever young:rejuvenating muscle satellite cells. Front Aging Neurosci, 2015. 7:37.
3. van Deursen, J.M., The role of senescent cells in ageing. Nature, 2014. 509:439-46.
4. Baker, D.J., et al., Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature, 2011. 479: 232-6.
5. Campisi, J., Cellular senescence:putting the paradoxes in perspective. Curr Opin Genet Dev, 2011. 21:107-12.
6. Blagosklonny, M.V., Cell cycle arrest is not senescence. Aging (Albany NY), 2011. 3:94-101.
7. Blagosklonny, M.V., Geroconversion:irreversible step to cellular senescence. Cell Cycle, 2014. 13:3628-35.
8. Campisi, J. and F. d'Adda di Fagagna, Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol, 2007. 8:729-40.
9. Kuilman, T., et al., The essence of senescence. Genes Dev, 2010. 24:2463-79.
10. Campisi, J. and L. Robert, Cell senescence:role in aging and age-related diseases. Interdiscip Top Gerontol, 2014. 39:45-61.
11. Demidenko, Z.N., et al., Rapamycin decelerates cellular senescence. Cell Cycle, 2009. 8:1888-95.
12. Benjamin, D., et al., Rapamycin passes the torch:a new generation of mTOR inhibitors. Nat Rev Drug Discov,2011. 10:868-80.
13. Leontieva, O.V., Demidenko, Z.N. and Blagosklonny, M.V. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget, 2015. p. 23238-23248.
14. Johnson, S.C., P.S. Rabinovitch, and M. Kaeberlein, mTOR is a key modulator of ageing and age-related disease. Nature, 2013. 493:338-45.
15. Blagosklonny, M.V., Why human lifespan is rapidly increasing:solving "longevity riddle" with "revealed-slowaging" hypothesis. Aging (Albany NY), 2010. 2:p. 177-82.
16. Sousa-Victor, P., et al., Geriatric muscle stem cells switch reversible quiescence into senescence. Nature, 2014. 506: 316-21.
17. Sousa-Victor, P., E. Perdiguero, and P. Munoz-Canoves, Geroconversion of aged muscle stem cells under regenerative pressure. Cell Cycle, 2014. 13:3183-90.